StAR related lipid transfer domain containing 10Genealiases: CGI-52 · NY-CO-28 · PCTP2 · SDCCAG28
Q-omics provides the consensus-scored STARD10 profile across patient tissues and cancer cell-line models. STARD10 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, STARD10 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, STARD10 protein abundance shows 26,336 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where STARD10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STARD10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STARD10 survival associations across molecular data types. STARD10 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STARD10 RNA expression–survival associations across cancer types. High STARD10 expression shows unfavorable associations in BLCA, but favorable associations in ACC, UCEC, LGG, BRCA and COAD. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for STARD10 RNA expression.
This table summarizes STARD10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for STARD10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STARD10 shows lower tumor expression in KIRP and KIRC and higher tumor expression in HNSC, BRCA, BLCA and STAD. The HNSC box plot shows higher STARD10 RNA expression in tumor versus normal tissue (log2 FC = +0.744, t-test p < 0.001).
This table shows molecular features associated with STARD10 in patient tissues and cancer cell lines. In patient samples, STARD10 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, STARD10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BREAST.
